FIELD: medicine.
SUBSTANCE: recombinant method is used to produce a microorganism of Mycobacterium tuberculosis complex which involves phoP gene inactivation or deletion and fadD26 gene inactivation or deletion. The produced microorganism is used for preventing tuberculosis in humans and animals.
EFFECT: invention allows producing the vaccine microorganism showing the properties of high attenuation and immune protection against tuberculous infection.
7 cl, 27 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR USE AS A PREVENTIVE AGENT FOR PATIENTS WITH A RISK OF TB INFECTION OR AS A SECONDARY AGENT FOR THE TREATMENT OF PATIENTS WITH TB INFECTION | 2019 |
|
RU2778094C2 |
| RECOMBINANT BCG OVEREXPRESSING PhoP-PhoR | 2017 |
|
RU2760580C2 |
| RECOMBINANT STRAIN OF INFLUENZA VIRUS A/PR8-NS124-TB10_4-2A-HSPX AND METHOD FOR SPECIFIC PREVENTION OF PULMONARY TUBERCULOSIS USING MUCOSAL VACCINE BASED THEREON | 2019 |
|
RU2726106C1 |
| RECOMBINANT INFLUENZA VIRUS STRAINS EXPRESSING MYCOBACTERIAL PROTECTIVE ESAT-6 ANTIGEN AND USES THEREOF IN TUBERCULOSIS TREATMENT AND PROPHYLAXIS | 2005 |
|
RU2318872C2 |
| STRAIN OF MYCOBACTERIUM TUBERCULOSIS BN FOR MODELLING LATENT TUBERCULOSIS INFECTION | 2021 |
|
RU2760751C1 |
| VACCINES OF RECOMBINANT INTRACELLULAR PATHOGENS AND USES THEREOF | 2001 |
|
RU2266132C2 |
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
| VACCINE AGAINST TUBERCULOSIS | 1999 |
|
RU2153354C1 |
| RECOMBINANT TUBERCULOUS VACCINE AND ADJUVANT FOR IT | 2017 |
|
RU2665817C1 |
| TUBERCULOSIS VACCINE WITH IMPROVED STRENGTH | 2004 |
|
RU2342400C2 |
